Pfizer Inc.,one of the world's largest research-based pharmaceutical companies, has reported that the company has completed the acquisition of Copenhagen-based Ferrosan Consumer Health’s business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited.

“Ferrosan Consumer Health’s innovative products and geographic footprint are a strong fit for our business,” said Paul Sturman, president, Pfizer Consumer Healthcare. “Today, we have taken an important step by adding leading brands to our existing portfolio as well as enhancing our presence in established and emerging markets such as the Nordic countries, Russia and Ukraine. Through this acquisition, we’ll have the opportunity to provide a broader portfolio of highly trusted and differentiated products to consumers.”

Ferrosan was founded in 1920 and has a long-standing pharmaceutical heritage. Headquartered in Copenhagen, Ferrosan Consumer Health today employs approximately 640 people and is engaged in the sale of science-based consumer health care products primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe.

The Altor funds (Altor) are private equity funds comprising the “Altor 2003 Fund”, with committed capital of EUR 650 million, the “Altor Fund II”, with committed capital of EUR 1,150 million and also the “Altor Fund III”, with committed capital of EUR 2,000 million. Altor is advised by Altor Equity Partners.